Risk Factors for Candida Infection among Children Admitted to a Pediatric Intensive Care Unit in a Tertiary Care Centre in Southern India

Raja Rajeshwari1, Siva Vyasam2, Jolly Chandran3, Sanketh Porwal4, Kala Ebenezer5, Muniya Thokchom6, Ebor J James7, Reka Karuppusami8

ABSTRACT

Background: To describe the clinical profile, risk factors, and outcomes that are associated with candida infection among critically ill children.

Patients and methods: A retrospective case-control study wherein 109 children admitted to the pediatric intensive care unit (PICU) in the years between 2015 and 2017 with the growth of candida from blood, urine, endotracheal (ET) aspirate, and pus swabs were included and compared to 97 age and sex-matched controls chosen from the same time period.

Results: Of the 124 candida isolates from 109 children, 37% were from blood, 24% from urine, and 14% in pus; 40% of the isolates were from ET aspirate. Candida non-albicans types (70%) predominated with Candida tropicalis causing 50% of the infections. Risk factors for candida infection were neutropenia [OR 20.01, 95% CI (0.94–422.32)], mechanical ventilation [OR 5.97, 95% CI (2.44–14.62)], peritoneal dialysis [OR 5.81, 95% CI (1.27–26.50)], institution of amino acids [OR 5.41, 95% CI (0.85–34.13)], presence of central venous catheter [OR 3.83, 95% CI (1.59–9.19)], antibiotic use > 5 days [OR 3.58, 95% CI (1.38–9.29)]. Candida Cases (95.4%) had a septic shock with acute kidney injury in 34% and had significantly lower survival than controls [72 (66%) of 109 vs. 74 (80%) of 92] (p = 0.023).

Conclusions: The rate of candida infection in our PICU was 4.2% of PICU admissions. The most common species was C. tropicalis. The independent risk factors for candida infection were neutropenia, antibiotic duration > 5 days, peritoneal dialysis, amino acid administration, mechanical ventilation, and presence of a central venous catheter (CVC).

Keywords: Candida, Pediatric intensive care unit, Risk factors.

Indian Journal of Critical Care Medicine (2022): 10.5005/jp-journals-10071-24203

HIGHLIGHTS

Any sick child in septic shock and ventilated needing central lines, parenteral nutrition, and antibiotic duration for more than 5 days should be screened for candida infection. Monitoring for candida colonization in critically ill children with the above risk factors could be a cost-effective strategy for the early detection of candida infections.

In a study done among 109 PICU children in South India who grew candida, C. non-albicans (70%) predominated. Risk factors for candida were: neutropenia, mechanical ventilation, peritoneal dialysis, amino acid infusion, and central venous catheter. Antibiotic use for over 5 days had three times the risk of developing candidiasis. Survival was significantly lower among those with candidiasis.

INTRODUCTION

Among critically ill infants and children, invasive fungal infection (IFI) has been of concern with candidiasis being more frequent than aspergillosis.1 Candida infections are the third most common cause of health care-associated bloodstream infections and the second most common cause of central catheter-associated bloodstream infections in children.2,3 Advancements in intensive care and the increased use of invasive procedures have led to a rise in invasive candida infections (ICI) in non-immunocompromised children that are considerably challenging to recognize and treat. As more families opt for chemotherapy and bone marrow transplants for childhood cancers, immunocompromised pediatric patients are a growing cohort in our setting.

Prolonged use of antibiotics, use of central venous catheters (CVCs), parenteral nutrition, renal replacement therapy, neutropenia, malignancy, and immunosuppressive therapies are the major risk factors for candida infections in ICUs.1

Among candida species, Candida albicans is the most common species in the pediatric population. However, in recent years the...
incidence of non-albicans types (C. glabrata, C. parapsilosis, C. krusei, and C. tropicalis) has increased. We attempted to identify predisposing factors in children who had candida in the PICU and their outcome in the Indian setting.

**Materials and Methods**

This study was conducted as a retrospective case-control study in the pediatric intensive care unit (PICU) of Christian Medical College Hospital, Vellore.

Cases were children aged 0 months to 15 years who were admitted to PICU from January 2015 to December 2017, and with the growth of candida in their blood, urine, endotracheal (ET) aspirate, or pus swabs. Controls were chosen during the same time period and were age and sex-matched.

In accordance with the CDC surveillance criteria, blood, urine, tracheal aspirate, and cultures were evaluated retrospectively. The presence of at least one type of candida in blood culture and the presence of concomitant fever, hypothermia, leukocytosis, elevation in acute phase reactants, tachycardia, and hypotension were evaluated as candidemia. In patients with new or progressive infiltrates on chest X-ray, the presence of two or more of the findings of fever >38°C or hypothermia, leukocytosis or leukopenia, purulent secretion, and candida isolation in tracheal aspirate culture was defined as pneumonia. Diagnosis of symptomatic urinary infection was made in the case of fever >38°C, and at least one of the signs and symptoms of urgency, frequency, dysuria or suprapubic tenderness, and isolation of candida species in the urine culture.

Cases were identified from an electronic medical database maintained by the computerized hospital information processing services (CHIPS) of the institution. Details of demographic profile, clinical presentation, laboratory investigations, and outcome with regards to PICU admission were collected from the in-patient charts and discharge summaries. Chest X-rays and CT scans were reviewed by the primary investigator and findings were noted. Variables such as duration of mechanical ventilation, duration of antibiotics, presence of a central venous catheter, and other risk factors were collected from the ICU flow sheet. Controls were selected from the PICU database, and their details were collected similarly. The datasheet was filled in by using standard pro forma which was then entered using EpiData software. The data thus collected were used to process the results needed to achieve the objectives.

**Statistical Analysis**

For continuous data that were skewed, median, and interquartile range (IQR) were done and categorical data were presented using numbers and percentages. Based on the normality assumption, a nonparametric Mann Whitney U test was used to evaluate the difference between cases and controls. The Chi-square, Fisher’s exact test (less cell count), and Yates continuity correction (zero count in the cell) were used to determine the association between categoric variables. All risk factors were assessed with binary logistic regression and penalized logistic regression analysis. Penalized logistic regression was used when the odds ratio could not be estimated due to empty cells or cells with low frequency, because of failure of the maximum likelihood estimate to converge. Point estimates were reported as odds ratio (OR) and 95% confidence interval (CI). All tests were two-sided at \( \alpha = 0.05 \) level of significance. Analyses were done using SAS® (Ver. 9.2, SAS Institute, and the USA).

**Results**

During the 3-year period, 109 children—47 (44%) in the year 2015, 34 (30%) in the year 2016, and 28 (26%) in the year 2017 were identified to have had candida infection from among 2,540 PICU admissions. In the age and sex-matched controls, 92 children had also been admitted during the same period. The median age among candida cases and controls was 7 (IQR 4–14.5) years and 6 (IQR 2–12) years, respectively. Infants were a major proportion of the study population in both groups (43 and 47%, respectively). Male predominance was also seen in both groups. Clinical characteristics and outcomes of candida cases and controls are compared and shown in Table 1.

Septic shock was the commonest PICU diagnosis (95%) followed by acute kidney injury (33.9%) and acute CNS infections (31.2%) among those with a candida infection. The other clinical diagnostic group among all children is shown in Figure 1. Eleven (10%) among candida cases had absolute neutrophilic count (ANC) less than 1.0 × 10^9/L whereas none of the controls were neutropenic.

There were 124 isolates of candida from 109 children as follows: endotracheal (ET) aspirate—42 (39%), blood—40 (37%), urine—27 (24%), and pus—15 (14%). Ten children had candida species isolated from two different sites, and one each had grown from more than two sites. Of the 42 who showed candida in their ET aspirates, 8 (19.9%) grew candida from other sites also. Ninety-nine (91%) of the cases had chest X-ray findings such as ground-glass opacities and perihilar infiltrates. Seven underwent CT scans of the thorax of which five showed findings suggestive of fungal pneumonia.

Of the 124 isolates, 33 (30%) were C. albicans, 55 (50%) were C. tropicalis, others were: C. glabrata—6 (5.5%), C. parapsilosis—5 (4.5%), C. krusei—1 (1%), and other candida species—9 (9%).

Multivariate analyses showed neutropenia [OR 20.01, 95% CI (0.94–422.32)], mechanical ventilation [OR 5.97, 95% CI (2.44–14.62)], peritoneal dialysis [OR 5.81, 95% CI (1.27–26.50)], institution of amino acids [OR 5.41, 95% CI (0.85–34.13)], central venous catheter in-situ [OR 3.83, 95% CI (1.59–9.19)], antibiotic use >14 days [OR 3.58, 95% CI (1.38–9.29)] to be significant factors associated with candida infection. Other risk factors that were less significant were infancy, previous admission and immunosuppression, and the presence of comorbidities (Table 2).

While 56 (51%) children were treated with fluconazole 59 (54%) had received amphotericin. Six had succumbed to the illness before the culture results became available. Among 109 candida cases 72 (66%) had survived whereas among controls there were 74 (80%) survivors; the difference achieved statistical significance (\( p = 0.023 \) (Table 1). There was no significant difference in the survival between albicans and non-albicans groups (24 [72%] vs 48 [63%], \( p = 0.33 \) (Fig. 2).

**Discussion**

In this retrospective study, we found six factors—neutropenia, mechanical ventilation, peritoneal dialysis, the institution of
Table 1: Clinical characteristics and outcome of the cases and controls

|                        | Cases (n = 109) n (%) | Control (n = 92) n (%) | p value |
|------------------------|-----------------------|------------------------|---------|
| Age (years)”a”         |                       |                        |         |
| <1 year                | 47 (43.1)             | 44 (47.8)              | 0.550   |
| 1–5 years              | 31 (28.4)             | 28 (30.4)              |         |
| 5–15 years             | 31 (28.4)             | 20 (21.7)              |         |
| Sex                    |                       |                        |         |
| Male                   | 63 (57.8)             | 58 (63.0)              | 0.449   |
| Female                 | 46 (42.2)             | 34 (37.0)              |         |
| Year                   |                       |                        |         |
| 2015                   | 47 (43.1)             | 31 (33.7)              | 0.283   |
| 2016                   | 34 (31.2)             | 29 (31.5)              |         |
| 2017                   | 28 (21.7)             | 32 (34.8)              |         |
| Clinical diagnosis     |                       |                        |         |
| Septic shock           | 104 (95.4)            | 24 (26.08)             | 0.177   |
| Acute kidney injury    | 37 (33.9)             | 4 (4.34)               |         |
| Duration of hospitalization (days) |       |                        |         |
| <5                     | 30 (27.5)             | 29 (31.52)             | 0.231   |
| 5–14                   | 37 (33.9)             | 38 (41.3)              |         |
| >14                    | 42 (38.53)            | 25 (27.17)             |         |
| Third line antibiotics |                       |                        |         |
| Cephalosporin          | 44 (39.4)             | 39 (42.39)             | 0.063   |
| Meropenem              | 100 (90.8)            | 46 (50.0)              |         |
| Vancomycin             | 25 (22.9)             | 23 (25.0)              |         |
| Aminoglycoside         | 34 (31.2)             | 16 (17.39)             |         |
| Meropenem + Vancomycin | 22 (20.18)            | 18 (19.56)             |         |
| System involvement     |                       |                        |         |
| Respiratory            | 14 (12.8)             | 6 (6.52)               | 0.455   |
| Cardiac                | 15 (13.8)             | 14 (15.2)              |         |
| Neurologic             | 29 (26.6)             | 10 (10.8)              |         |
| Renal                  | 11 (10.3)             | 4 (4.34)               |         |
| Endocrine              | 13 (11.9)             | 4 (4.34)               |         |
| Chronic liver disease  | 1 (0.9)               | 1 (1.08)               |         |
| Post-operative         | 14 (12.8)             | 11 (11.9)              |         |
| Burns                  | 4 (3.7)               | 2 (2.17)               |         |
| Outcome                |                       |                        |         |
| Alive                  | 72 (66.1)             | 74 (80.4)              | 0.023   |
| Death                  | 37 (33.9)             | 18 (19.6)              |         |

"a"Values are presented as Median (IQR) and p value is obtained from the Mann Whitney test; Values are presented as n (%) and p value is obtained from Chi-square and Fishers exact test.

Fig. 1: Clinical diagnosis of children with invasive candida infection
Risk Factors for Candida Infection in Critically Ill Children

Table 2: Risk factors for candida infection

| Risk factors               | Cases       | Controls     | p value* | OR (95% CI)  | aOR (95% CI) | p value† |
|----------------------------|-------------|--------------|----------|--------------|--------------|----------|
| Age (years)                |             |              |          |              |              |          |
| <1                         | 47 (43.1)   | 44 (47.8)    | 0.69     | 0.34, 1.38   | 0.295        | 0.62     |
| 1–5                        | 31 (28.4)   | 28 (30.4)    | 0.71     | 0.33, 1.53   | 0.385        | 0.33     |
| 5–15                       | 31 (28.4)   | 20 (21.7)    | 0.550    |              |              |          |
| Presence of co-morbidities | 72 (66.1)   | 48 (52.2)    | 0.046    | 1.78, 3.15   | 0.046        | 1.58     |
| Neutropenia (ANC <1000)    | 11 (10.1)   | 0 (0.0)      | 0.005    | 21.63, 422.92| 0.043        | 20.01    |
| Immunosuppressants         | 13 (11.9)   | 7 (7.6)      | 0.308    | 1.64, 4.31   | 0.312        | 1.09     |
| Duration of antibiotics (>5 days) | 46 (42.2) | 29 (31.5)   | 0.002    | 3.89, 9.03   | 0.002        | 3.58     |
| Peritoneal dialysis        | 13 (11.9)   | 2 (2.2)      | 0.009    | 6.09, 27.76  | 0.019        | 5.81     |
| Institution of amino acids | 11 (10.1)   | 1 (1.1)      | 0.007    | 10.21, 80.69 | 0.028        | 5.41     |
| Mechanical ventilation     | 96 (88.1)   | 57 (62.0)    | <0.0001  | 4.53, 9.29   | <0.0001      | 5.97     |
| Presence of central venous line | 37 (33.9) | 11 (12.0) | <0.0001  | 3.78, 7.96   | <0.0001      | 3.83     |

*p value is obtained from Chi-square test; †p value is obtained from univariate logistic regression and penalized logistic regression; §p value is obtained from the multiple penalized logistic regression

A strong trend towards a preponderance of infant population with high rates of ventilatory support in a large case volume PICU. The inclusion of clinically suspect VAP (new-onset fever, purulent secretions, or increasing ventilatory requirements) rather than those with routine surveillance cultures is in favor of an infection rather than incidental colonization. The X-ray chest findings seen in all of them further support this. Differentiating candida colonization of the respiratory tract from VAP can be challenging. Candida score has been proposed and all our cases had a score >2.5 cut off. In children, candidal colonization and biofilm formation can worsen pulmonary inflammation resulting in prolonged ventilation with higher morbidity and mortality.

C. albicans remains the most common species of candida in Australia, France, South Africa and North American PICUs as well as in the 5-year retrospective pediatric study from Saudi Arabia. Other studies, however, report more non-albicans types of candida, C. glabrata being the highest. Even those studies that reported a preponderance of C. albicans observe a strong trend towards the emergence of candida non-albicans. Indian studies from PICUs identified C. tropicalis, C. parapsilosis, and C. albicans as common isolates similar to ours. In the non-albicans candida (NAC) study from UK NAC was isolated more frequently in those with hematological malignancies and bone marrow transplant (BMT) recipients but was less common among ICU and surgical children. Management guidelines for ICI in pediatric patients suggest the use of fluconazole, echinocandins, and amphotericin B. We had treated our patients equally with intravenous amphotericin or fluconazole. The growing incidence of non-albicans infections poses a challenge in resource-limited settings as they are often resistant to azoles necessitating treatment with either amphotericin or echinocandins. Echinocandins and liposomal amphotericin are prohibitively expensive. The side effects of conventional amphotericin such as fever, hypersensitivity reaction, and hypokalemia warranting large doses of potassium replacement are a concern. Recently new orally effective drugs are available like posaconazole, and isavuconazole but cost is a limiting factor.

The mortality rates of invasive candidiasis vary from 22 to 55% with the overall attributable mortality of C. tropicalis and C. glabrata being the highest. In our study, those children with candida infection had significantly lower survival than controls as in other studies. We however did not find any significant difference in the survival between C. albicans and non-albicans groups of our population. Our study besides being a single-center...
Risk Factors for Candida Infection in Critically Ill Children

study was also of retrospective design and hence clinical data on each patient was dependent on what was documented in the charts, which is a limitation.

Close monitoring of critically ill children with the above risk factors could be a cost-effective strategy for the early detection of candida infections.

CONCLUSION
The rate of candida infection is 4.2% of PICU admissions. The most common species was C. tropicalis. The independent risk factors for candida infection were neutropenia, antibiotic duration >5 days, peritoneal dialysis, amino acid administration, mechanical ventilation, and presence of CVC.

Research Quality and Ethics Statement
The authors of this manuscript declare that this scientific work complies with reporting is IRB Min no: 11416 dated June 3, 2018. We also certify that we have not plagiarized the quality, formatting, and reproducibility guidelines set forth by the EQUATOR network. The authors also attest that this clinical investigation was determined to require an Institutional Review Board/Ethics Committee review, and the corresponding protocol/approval number the contents in this submission and have done a Plagiarism Check.

ORCID
Raja Rajeshwari https://orcid.org/0000-0001-6680-6611
Siva Vyasam https://orcid.org/0000-0002-0887-1535
Jolly Chandran https://orcid.org/0000-0003-0021-8897
Sanketh Porwal https://orcid.org/0000-0003-2841-0055
Muniya Thokchom https://orcid.org/0000-0003-3932-9025
Ebor J James https://orcid.org/0000-0001-6302-6572
Reka Karuppusami https://orcid.org/0000-0001-9913-2713

REFERENCES
1. Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 2014;5(1):161–169. DOI: 10.4161/viru.26187.
2. ElGendy FM, Hassan FM, Khatab AA, El-Hendawy GR, Saleh NY. Study of fungal infections in pediatric intensive care unit in Menoufia University Hospital. Menoufia Med J 2014;27(1):55. DOI: 10.4103/11-2008.132742.
3. Mesini A, Bandettini R, Caviglia I, Fioredda F, Amoroso L, Faraci M, et al. Candida infections in paediatrics: results from a prospective single-centre study in a tertiary care children’s hospital. Mycoses 2017;60(2):118–123. DOI: 10.1111/myc.12570.
4. Orasch C, Mertz D, Garbino J, van Delden A, Emonet S, Schrenzel J, et al.; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009;123(5):1360–1368. DOI: 10.1542/peds.2008-2055.
5. Devrić I, Demiragic B, Yaman Y, Bayram N, Ozdemir F, Kara A, et al. A 7-year study of the distribution of nosocomial candidemia in children with cancer. Turk J Pediatr 2015;57(3):225–229. PMID: 26701939.
6. Almoosa Z, Ahmed GY, Omran A, AlSaheef A, Alturki A, Alaqeel A, et al. Invasive candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia. A 5-year retrospective study. Saudi Med J 2017;38(11):1118–1124. DOI: 10.15537/smj.2017.11.2116.
7. Singh S, Rao DSVR, Chakraborti A. Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med 2008;9(1):91–95. DOI: 10.1097/PCC.0b013e31812653f0.
8. Conde-Rosa A, Amador R, Pérez-Torres D, Colón E, Sánchez-Rivera C, Nieves-Plaza M, et al. Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center. P R Health Sci J 2010;29(1):26–29. PMID: 20222330.
9. Brissaud O, Guichoux J, Harambat J, Tandonnet O, Zaoutis T. Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care 2012;2(1):6. DOI: 10.1186/2110-5820-2-6.
10. Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010;51(5):e38–e45. DOI: 10.1086/655698.
11. Aslan N, Yildizdas D, Alabaz D, Horoz OO, Yontem A, Kocabas E. Invasive candida infections in a pediatric intensive care unit in Turkey: evaluation of an 11-year period. J Pediatr Intensive Care 2020;9(1):21. DOI: 10.1055/s-0039-1695061.
12. Acar A, Oncu O, Kucukkardali Y, Ozurt M, Haznedaroğlu T, Cavuşlu S. Epidemiological features of candida infections detected in intensive care units and risk factors affecting mortality. Microbiyul 2008;42(3):451–461. PMID: 18822889.
13. Sütçü M, Acar M, Genç GE, Kökçü İ, Aktürk H, Atay G, et al. Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis. Turk Pediatr Arş 2017;52(3):145–153. DOI: 10.5152/TurkPediatriArş.2017.5291.
14. Delisle MS, Williamson DR, Albert M, Perreault MM, Jiang X, Day AG, et al. Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia. Can Respir J 2011;18(3):131–136. DOI: 10.1155/2011/827692.
15. De Pascale G, Antonelli M. Candida colonization of respiratory tract: to treat or not to treat, will we ever get an answer? Intensive Care Med 2014;40(9):1381–1384. DOI: 10.1007/s00134-014-3364-y.
16. Dramowski A, Cotton MF, Whitelaw A. Surveillance of healthcare-associated infection in hospitalised South African children: which method performs best? South Afr Med J 2017;107(1):56–63. DOI: 10.7196/SAMJ.2016.v107i1.11431.
17. Palazzi DL, Arrieta A, Castagnola E, Halasa N, Hubbard S, Brozovich AA, et al. Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multinational study. Pediatr Infect Dis J 2014;33(12):1294–1296. DOI: 10.1097/INF.0000000000000431.
18. Çekin Y, Pekintürk N, Çekin AH. Evaluation of species distribution and antifungal resistance of Candida isolates from hospitalized patients. J Clin Anal Med 2015;4(6):198–202. DOI: 10.1086/655698.
19. Hazrulan G, Yildiran D, Baran I, Mumcuoglu I, Akus N. Yatan hemato nörolojik hastaliklar ve antifungal duyarlılık profillerinin değerlendirilmesi. Turk Hij Den ve antifungal duyarlılık profilerinin değerlendirilmesi. Turk Hij Den 2015;40(9):1381–1384. DOI: 10.1007/s00134-014-3364-y.
20. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health-care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36(5):309–332. DOI: 10.1016/j.ajic.2008.03.002.
21. Blly CC, Chen SC, Slavin MA, Serena C, Nguyen Q, Marriott D, et al.; Australian Candidemia Study. Not just little adults: candidemia
of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:1–50. DOI: 10.1093/cid/civ933.

26. Hope WW, Castagnola E, Groll AH, Rollides E, Akova M, Arendrup MC, et al.; ESCMID Fungal Infection Study Group. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012;18(Suppl 7): 38–52. DOI: 10.1111/1469-0691.12040.

27. Hlophe ST, Govender NP, Masekela R. Invasive fungal infections among critically ill children: epidemiology, risk factors and outcomes. Afr J Thorac Crit Care Med 2018;24(1):11–14. DOI: 10.7196/AJTCCM.2018.v24i1.172.

28. Arendrup MC, Sulim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011;49(9):3300–3308. DOI: 10.1128/JCM.00179-11.